Max Reif

Max C Reif , MD

Medical Sciences Building
Room G263
231 Albert Sabin Way
Cincinnati, Ohio 45267
Phone 513-558-5471
Fax 513-558-4309
Email max.reif@uc.edu

Professional Summary

Professor of Medicine

Education

Bachelor's Degree: University of Basel School of Medicine 1969 (Pre-Med)

Medical Degree: University of Lausanne School of Medicine 1973

Residency: University of Lausanne Medical Center 1975 (Pathophysiology )

Residency: New York Infirmary 1977 (Internal Medicine )

Fellowship: Mt. Sinai School of Medicine 1981 (Renal Diseases )

Certifications

American Board of Internal Medicine (Certification Date: 09-13-1978 )

American Board of Internal Medicine (Nephrology) (Certification Date: 11-09-1982 )

Clinical Interests

Nephrology

Specialities

Internal Medicine

Nephrology

Research and Practice Interests

The Genetic Background of Salt Metabolism and Its Relationship to Hypertension, Cardiovascular Risk Reduction, Hypertension, Metabolic Syndrome, Hyperlipidemia and Heart Failure.

Positions and Work Experience

1998 -To Present Professor of Medicine (Clinical Track), University of Cincinnati, Cincinnati, OH

1990 -1998 Associate Professor of Medicine, University of Cincinnati, Cincinnati, OH

1988 -1989 Associate Professor of Medicine, University of Alabama at Birmingham,

1983 -1988 Assistant Professor of Medicine, University of Alabama at Birmingham,

1981 -1983 Instructor of Medicine, University of Alabama in Birmingham,

1980 -1981 Instructor of Medicine, Mt. Sinai School of Medicine,

Research Support

Investigators:Thornley-Brown D, Reif MC 1992 -1993 Cincinnati Kidney Foundation Pathogenesis of Renal Failure in Sickle Cell Anemia Role:Co-Investigator Completed

Investigators:Galla J, Reif MC 1990 Miles, Inc Double Blind, Randomized Study of the Safety and Efficacy of Once Daily Doses of Nisoldipine 20, 40 and 60mg Core Coated Tablets vs. Placebo in Combination with Atenolol 50mg in Hypertensive Patents. Role:Co-Investigator Completed

Investigators:Reif MC 1991 Marion Merrell Dow, Inc Assessment of the Safety and Efficacy of Diltiazem QD in Patients Whose Hypertension is Controlled by Cardizem SR. Role:PI Completed

Investigators:Reif MC 1992 Marion Merrell Dow, Inc A Dose-Response Trial of Ro 40-5967 Administered Once Daily for the Treatment of Essential Hypertension. Role:PI

Investigators:Reif MC 1992 Miles, Inc A Double-Blind, Randomized, Parallel Group, Comparative Study of the Safety and Efficacy of Nifedipine Coat-Core (30mg and 60mg daily) vs. Nifedipine GITS (30mg and 60mg daily) in patients with Mild to Moderate Hypertension. Role:PI Completed

Investigators:Reif MC 1993 Miles, Inc An Open-Label Study of the Safety of Long-Term Therapy with Nifedipine Coat-Core 90mg Taken Once Daily with Food in Patients with Mild to Moderate Hypertension. Role:PI Completed

Investigators:Reif MC 1995 Merck & Co., Inc COZ345 Losartan vs. Nifedipine in the Elderly. Role:PI Completed

Investigators:Reif MC 1993 Miles, Inc A Double-Blind Pilot Study of Ecadotril 50mg, 100mg and 200mg Twice Daily Compared to Placebo in Patients with Hypertension. Role:PI Completed

Investigators:Reif MC 1995 Laboratories UPSA Open-Label Extension of the Dose-Range and Short-Term Efficacy Study of UP 269-6 in Hypertensive Patients. Role:PI Completed

Investigators:Reif MC 1994 Marion Merrell Dow, Inc Diltiazem ER/Enalapril Combination Therapy in Hypertensive Patients Not Responding Adequately to Diltiazem CD (Cardizem CD) Monotherapy. Role:PI Completed

Investigators:Reif MC 1995 Bayer, Corp. Randomized, Double-Blind, Multicenter Trial of Ecadotril vs. Placebo in Essential Hypertension; D94-027. Role:PI Completed

Investigators:Reif MC 1994 Laboratories UPSA A Phase II, Double-Blind, Placebo Controlled Dose-Range Study and Short-Term Efficacy Study of UP 269-6 in Hypertensive Patients. Role:PI Completed

Investigators:Reif MC 1995 Astra Merck, Inc. Evaluation of the Efficacy and Safety of Candesartan Cilexetil in the Treatment of Patients with Hypertension: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study. Role:PI Completed

Investigators:Reif MC 1996 Sankyo U.S.A. Corp. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of CS-866 Using Ambulatory Blood Pressure Monitoring in Hypertensive Patients. Role:PI Completed

Investigators:Reif MC 1996 Astra Merck, Inc. Comparison of the Safety and Antihypertensive Efficacy of the Fixed Combination of Candesartan Cilexetil and Hydrochlorothiazide Once Daily with the Individual Components Given Once Daily: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Design Study. Role:PI Completed

Investigators:Reif MC 1996 Merck & Co., Inc A Prospective, Double-Blind, Randomized, Parallel Study of the Effects of the Non-Steroidal Anti-Inflammatory Drug Indomethacin on the Antihypertensive Response to Losartan Versus Captopril in Patients With Essential Hypertension. Role:PI Completed

Investigators:Reif MC 1997 G.D. Searle & Co. Efficacy and Safety Evaluation of a Range of Doses of SC-66110 in the Treatment of Mild to Moderate Hypertension. Role:PI Completed

Investigators:Reif MC 1997 Astra Merck, Inc. Comparison of the Safety and Antihypertensive Efficacy of the Fixed Combination of Candesartan Cilexetil and Hydrochlorothiazide (32/12.5 mg) Once Daily with the Individual Components Administered Once Daily: A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Designed Study. Role:PI Completed

Investigators:Reif MC 1997 Merck & Co., Inc A Double-Blind, Randomized, Parallel Effectiveness Study of Two Hypertensive Treatment Regimens; Losartan versus Valsartan in Patients With Mild to Moderate Essential Hypertension. Role:PI Completed

Investigators:Reif MC 1998 Merck & Co., Inc A Triple-Blind, Randomized, Parallel Efficacy Study of Losartan versus Irbesartan in Patients With Mild to Moderate Essential Hypertension. Role:PI Completed

Investigators:Reif MC 1998 Bristol-Myers Squibb A Multicenter, Randomized, Double-Blind Trial of the Antihypertensive Efficacy and Safety of Irbesartan Compared with Amlodipine for the Treatmnent of Mild-to-Moderate Hypertension. Role:PI Completed

Investigators:Reif MC 1998 Eli Lilly & Co Open Label Safety of Sustained-Release (SR) Moxonidine in Stage 1 and Stage 2 Hypertension. Role:PI Completed

Investigators:Reif MC 1999 Sankyo U.S.A. Corp. A Randomized, Double-Blind, Parallel Group, Comparative Study of CS-866, Losartan, Valsartan and Irbesartan Using Ambulatory Blood Pressure Monitoring in Patients with Essential Hypertension. Role:PI Completed

Investigators:Reif MC 1999 AstraZeneca LP Evaluation of the Antihypertensive Efficacy of Candesartan Cilexetil in Comparison to Losartan: A Multicenter, Double-Blind, Randomized, Parallel Group, Forced-Titration Study. Role:PI Completed

Investigators:Reif MC 2000 Merck & Co., Inc A Double-Blind, Randomized, Parallel, Placebo-Controlled, Efficacy Study of Losartan Potassium 100mg - Hydrochlorothiazide 25mg versus Losartan Potassium 50mg - Hydrochlorothiazide 12.5mg in Patients with Essential Hypertensions. Role:PI Completed

Investigators:Reif MC 2000 Merck & Co., Inc A Prospective, Double-Blind, Randomized, Parallel Efficacy Study of a Losartan Treatment Regimen versus Placebo in the Treatment of Patients with Isolated Systolic Hypertension. Role:PI Completed

Investigators:Reif MC 2001 Bristol Myers Squibb Omapatrilat Cardiovascular Treatment Assessment versus Enalapril. Role:PI Completed

Investigators:Reif MC 2001 AstraZeneca LP Antihypertensive Efficacy of Adding Candesartan Cilexetil to Lisinopril in Comparison to Up-titration of Lisinopril. Role:PI Completed

Investigators:Reif MC 2001 Merck & Co., Inc A Randomized, Double-Blind, Safety and Efficacy Pilot Study of Losartan-Hydrochlorothiazide versus Rampipril as First-Line Antihypertensive Therapy in Patients with Type 2 Diabetes Mellitus and Hypertension. Role:PI Completed

Grant: #SRS 005015 Investigators:Effat, Mohamed; Gerson, Myron; Reif, Max; Syed, Faisal 07-01-2007 -12-31-2008 American Society of Nuclear Cardiology Sympathetic Nervous Modulation in Hypertension by Beta-Adrenergic Blockade Role:Collaborator $25,000.00 Closed Level:Private Non-Profit

Grant: #SRS 005979 Investigators:Reif, Max 03-01-2005 -08-31-2005 Schering-Plough Corporation The Management of Hyperlipidemia in Patients with Kidney Diseases Role:PI $2,100.00 Closed Level:Industry

Publications

Published Abstracts

Abramson RG, Reif M, King VF, Leal-Pinto E, Baruch SB (1979. ) Role of copper in urate transport and oxidation by membrane vesicles of rat renal cortex. Am Soc Nephrol, 12 (32A ) ,Co-Author

Abramson RG, Reif MC, King VF, Leal-Pinto E, Baruch, SB (1980. ) Effect of copper on urate transport on chloride permeability in membrane vesicles from rat renal cortex. Renal Physiol, Fed Proc 39 (2436 ) ,Co-Author

Abramson RG, Baruch SB, Reif MC, Leal-Pinto E, King VF (1980. ) Apparent dependence of urate transport on chloride permeability in membrane vesicles from rat renal cortex. Renal Physiol, 2(3) (20 ) ,150Co-Author

Reif MC, Schafer JA (1984. ) Arginine vasopressin (ADH) induces a stable increase in rat Na+ absoprtion by rat cortical collecting tubule. Fed Proc, 43 (108 ) ,Co-Author

Reif MC, Troutman SL, Schafer JA (1984. ) Water permeability response of rat collecting tubules to ADH. Kidney Int, 25 (1 ) ,314Co-Author

Reif MC, Schafer JA (1985. ) Prostaglandin E2 does not inhibit vasopressin action in the isolated perfused rat cortical collecting tubule. Kidney Int, 27 (1 ) ,332Co-Author

Reif MC, Bindels RJM, Schafer JA (1987. ) Regulation of Na+ transport by aldosterone and arginine vasotocin (AVT) in cultured kidney A6 cells. .[Abstract]Am Soc Nephrol, 136A ,Co-Author

Bindels RJM, Schafer JA, Reif MC (1987. ) Stiumulation of Na+ transport by novobiocin in cultured kidney A6 cells. Am Soc Nephrol, 269A ,

Chen L, Parris M, Willilams SK, Reif MC, Schafer JA (1989. ) Different effects of clonidine and prostaglandin E2 on vasopressin response of rat and rabbit cortical collecting duct. Nephrol, 178A ,Co-Author

Peer Reviewed Publications

Reif MC, Constantiner A, Levitt MF (1981. ) Chronic gouty nephropathy: A vanishing syndrome? .N Engl J Med, , 304 ,535

Abramson RG, King VF, Reif MC, Leal-Pinto E, Baruch SB (1982. ) Urate uptake in membrane vesicles of rat renal cortex: Effect of copper .Am J Physiol, , 242 ,F158 -F170

Reif MC, Troutman SL, Schafer JA (1984. ) Sustained response to vasopressin in isolated rat cortical collecting tubule .Kidney Int, , 26 (5 ) ,725 -732

Wall B, Keller FS, Spalding MD, Reif MC (1986. ) Massive hemorrhage from a lumbar artery following percutaneous renal biopsy .Am J Kidney Dis, , 7 (3 ) ,250 -253

Reif MC, Troutman SL, Schafer JA (1986. ) Sodium transport by rat cortical collecting tubule. Effects of vasopressin and desoxycorticosterone .J Clin Invest, , 77 (4 ) ,1291 -1298

Bindels RJM, Schafer JA, Reif MC (1998. ) Stimulation of sodium transport by aldosterone and arginine vasotocin in A6 cells .Biochim Biophys Acta, , 972 ,320 -330

Chen L, Reif MC, Schafer JA (1991. ) Clonidine and PGE2 have different effets on Na+ and water transport in the rat and rabbit CCT .Am J Physiol, , 261 ,F126 -F136

Reif MC, Carter V (1994. ) The retail cost of antihypertensive therapy. Physician and patient as educated consumers .AM J Hypertens, , 7 ,571 -575

Reif MC, Hanto DW, Moulton JS, Alspaugh JP, Bejarano P (1996. ) Primary hepatic pheochromocytoma .AM J Hypertens, , 9 ,1040 -1043

Hebert LA, Agarwal G, Ladson-Wofford SE, Reif MC, Hiremath L, Carlton SG, Nahman NS, Falkenhain ME, Agarwal A (1996. ) Nocturnal blood pressure in treated hypertensive African-Americans compared to treated hypertensive European Americans. J Am Soc Neph, , 7 ,2130 -2134

Su YR, Rutkowski MP, Klanke CA, Wu X, Pun RYK, Carter V, Gartside PS, Reif MC, Menon A (1996. ) A novel variant of the amiloride-sensitive sodium channel beta-subunit in African Americans is associated with enhanced cAMP responsiveness .J Am Soc Neph, , 7 ,2543 -2549

Oparil S, Kobril I, Abernethy DR, Levine BS, Reif MS, Shepherd AM (1997. ) Dose-response characteristics of mibefradil, a novel calcium channel antagonist, in the treatment of essential hypertension .AM J Hypertens, , 10 ,735-742

Cui Y, Su YR, Rutkowski M, Reif M, Menon AG, Pun RYK (1997. ) Loss of protein kinase C (PKC) inhibition in the beta T594M variant of the amiloride-sensitive sodium channel .Pro Natl Acad Sci, , 94 ,9962 -9966

Onions K, Hunt SC, Rutkowski MP, Klanke CA, Su YR, Reif MC, Menon AG (1998. ) Genetic markers at the leptin locus are not linked to hypertension in African Americans .Hypertension, , 31 ,1230 -1234

Reif MC, White W, Fagan T, Oparil S, Flanagan TL, Edwards DR, Cushing DJ, Michelson EL (1998. ) Effects if candesartan cilexitil in patients with systemic hypertension .Am J Cardiol, , 82 ,961 -965

Reif MC (2000. ) New hope for protecting the kidneys from hypertension .Drug Benefit Trades, , 12(supplement E) ,17 -23

Papademetriou V, Reif M, Henry D, Neutel JM, Levine JH, Hardison JD, Flanagan T, Michelson EL (2000. ) Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension .J Clin Hypertens, , 1 ,2 -8

Reif MC (2000. ) The pharmaceutical industry - to whom is it accountable? .N Engl J Med, , 343 ,1415 -1416

Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson E, Wang R and the CLAIM study investigators (2001. ) Antihypertensive efficacy of candesartan in comparison to losartan. The CLAIM study .J Clin Hypertens, , 3 ,16 -21

Kishore BK, Krane CM, Reif MC, Menon AG (2001. ) Urinary concentration defect in the elderly population: Insights from recent advances in physiology and pathophysiology of renal aquaporins .Int Urol and Nephrol, , 33 ,235 -248

Invited Publications

Reif, MC (2003. ) Managing hypertension in pregnancy .Woman Health Primary Care, 6 ,164 -200

Reif MC (2003. ) How to identify and manage preeclampsia .Woman Health Primary Care, 6 ,194 -200

Reif MC (2003. ) Clinical Cutout: Hypertension and preeclampsia in pregnancy .Woman Health Primary Care, 6 ,244

Book Chapter

Luke, RG; Reif, MC (1995 ) Cardiovascular System in Uremia - Hypertension. Textbook of Nephrology (3rd Edition) .Baltimore, Williams & Wilkins (Co-Author)

Luke, RG; Reif, MC (2003 ) Cardiovascular System in Uremia - Hypertension. Textbook of Nephrology (4th Edition) .(pp. 1305).Baltimore, Williams & Wilkins (Co-Author)

Reif, MC (2008 ) Hypertension The 5 Minute OB/GYN Consult .Philadelphia, Lippincott Williams & Wilkins (Author)

Reif, MC (2010 ) Hypertension Treatment Strategies for Common Medical Problems .Andra Pradesh, India, Assess and Intervene Trust (Author)

Reif, MC (2010 ) Hypertensive Emergency and Urgency Treatment Strategies for Common Medical Problems .Andra Pradesh, India, Assess and Intervene Trust (Author)

Presentations

Invited Presentations

Reif, MC (02-26-2005. ) The Heart of the Matter: Focusing on Sympathetic Blockade in the Prevention and Treatment of Heart Failure .Phoenix, AZ. Conference. . Level:Prof. Org.

Reif, MC (03-09-2005. ) Stroke Prevention for the Clinical Specialist .Department of Family Practice, Grant Medical Center, Columbus, OH. Other Institution. . Level:Regional

Reif, MC (03-12-2005. ) The Heart of the Matter: Focusing on Sympathetic Blockade in the Prevention and Treatment of Heart Failure .Stamford, CT. Conference. . Level:Prof. Org.

Reif, MC (03-31-2005. ) Preventing Stroke 2005: Focus on the Patient at Risk .Cincinnati, OH. UC. . Level:University

Reif, MC (04-01-2005. ) Setting New Sights: Why Benefits Outweight Risks in Dyslipidemia Management .Anaheim, CA. Other Institution. . Level:University

Reif, MC (04-08-2005. ) The Heart of the Matter: Focusing on Sympathetic Blockade in the Prevention and Treatment of Heart Failure .Denver, CO. Conference. . Level:Prof. Org.

Reif, MC (05-11-2005. ) CV Risk Associated with Obesity and Metabolic Syndrome .Columbus, OH. Other Institution. . Level:University

Reif, MC (06-17-2005. ) Setting New Sights - Achieving New Targets: Why Benefits Outweigh the Risks in Dyslipidemia Management .Rosemont, IL. Conference. . Level:Prof. Org.

Reif, MC (07-29-2005. ) Cardiovascular Risk: Obesity and Metabolic Symdrome .Grand Rapids, MI.

Reif, MC (07-13-2005. ) Skin and Bones: Calcium and the Kidney .Department of Medicine, University of Cincinnati.

Reif, MC (09-09-2005. ) Contemporary Diagnosis and Outpatient Management of Chronic Heart Failure: Increasing Importance of RAAS .Birmingham, AL. Conference. .

Reif, MC (11-05-2005. ) The Heart of the Matter: Focusing on Sympathetic Blockade in the Prevention and Treatment of Heart Failure .Cleveland, OH. Conference. . Level:Prof. Org.

Reif, MC (11-09-2005. ) Finding Common Ground: Optimizing Treatment of Cardiovascular Disease in Controversial Populations .Wright State University, Dayton, OH.

Reif, MC (11-16-2005. ) Calcium Metablism and Chronic Kidney Disease .Department of Cardiology, University of Ferarra, Italy.

Reif, MC (11-30-2005. ) Contemporary Diagnosis and Outpatient Management of Chronic Heart Failure: Increasing Importance of RAAS .Portland, OR. Conference. . Level:Prof. Org.

Reif, MC (12-07-2005. ) Dyslipidemia: A Practical Approach .Cardiology Fellowship Program, Ohio State University, Columbus, OH.

Reif, MC (12-09-2005. ) The Heart of the Matter: Focusing on Sympathetic Blockade in the Prevention and Treatment of Heart Failure .Miami, FL. Conference. . Level:Prof. Org.

Reif, MC (12-10-2005. ) Contemporary Blood Pressure Management: Focusing on Patients at High Risk for Cardiovascular Disease .Milwaukee, WI. Conference. . Level:Prof. Org.

Reif, MC (01-18-2006. ) Finding Common Ground: Optimizing Treatment of Cardiovascular Disease in Controversial Populations .St. Vincent's Mercy Hospital, Toledo, OH. Other Institution. .

Reif, MC (01-31-2006. ) Finding Common Ground: Optimizing Treatment of Cardiovascular Disease in Controversial Populations .Dunlap Memorial Hospital, Orrville, OH. Other Institution. .

Reif, MC (02-02-2006. ) Practical Treatment of Hypertension .Cardiology Fellowship Program, University of Cincinnati.

Reif, MC (02-10-2006. ) The Treatment of Hypertension in 2006 .Division of Nephrology, University of Cincinnati.

Reif, MC (03-09-2006. ) Evaluation and Treatment of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .Cleveland, OH. Level:Prof. Org.

Reif, MC (03-10-2006. ) Evaluation and Treatment of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .Birmingham, AL. Other Institution. . Level:Prof. Org.

Reif, MC (03-16-2006. ) Hypertension and Pregnancy .Nephrology Fellowship Program, University of Cincinnati.

Reif, MC (04-01-2006. ) Evaluation and Treatment of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .Salt Lake City, UT. Level:Prof. Org.

Reif, MC (05-12-2006. ) Evaluation and Outpatient Management of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .Toledo, OH. Level:Prof. Org.

Reif, MC (09-07-2006. ) Managing the Hypertension Continuum: From Pre-Hypertension to Compelling Indications .Grand Rapids, MI. Conference. . Level:Prof. Org.

Reif, MC (10-05-2006. ) Evaluation and Outpatient Management of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .Oakbrook, IL. Conference. . Level:Prof. Org.

Reif, MC (12-08-2006. ) Evaluation and Outpatient Management of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .San Antonio, TX. Conference. . Level:Prof. Org.

Reif, MC (12-15-2006. ) Evaluation and Outpatient Management of Chronic Heart Failure: Increasing Emphasis on Triple Neurohormonal Blockade .Milwaukee, WI. Conference. . Level:Prof. Org.

Reif, MC (03-27-2007. ) Insider's Guide to Dyslipidemia: A Practical Guide to Global Risk Stratification and Lipid Management .St. Paul, MN. Conference. . Level:Prof. Org.

Reif, MC (04-19-2007. ) Insider's Guide to Dyslipidemia: A Practical Guide to Global Risk Stratification and Lipid Management .Rochester, NY. Conference. . Level:Prof. Org.

Reif, MC (04-25-2007. ) Insider's Guide to Dyslipidemia: A Practical Guide to Global Risk Stratification and Lipid Management .Rosemont, IL. Conference. . Level:Prof. Org.

Reif, MC (04-26-2007. ) Hypertension and Pregnancy .Kentucky Coalition of Nurse Practitioners/Nurse Midwives, 19th Regional Conference, Covington, KY.

Reif, MC (05-15-2007. ) Renin Angtiotensin System Inhibition in Hypertension .Department of Family Practice, University of St. Louis, Belleville, IL.

Reif, MC (06-02-2007. ) A Clinical Approach to Chronic Kidney Disease (CKD) .Kidney Foundation of Greater Cincinnati, Cincinnati, OH.

Reif, MC (06-02-2007. ) CKD and Bone Disease and Preventing Progression: The Holy Grail of CKD .Kidney Foundation of Greater Cincinnati, Cincinnati, OH.

Reif, MC (08-15-2007. ) The Renin-Angiotensin-Aldosterone System: Why Do We Have It and Do We Still Want It? .Department of Medicine, University of Cincinnati.

Reif, MC (09-19-2007. ) Update on Hypertension .Department of Medicine, Providence Hospital, Southfield, MI.

Reif, MC (09-19-2007. ) New Perspective on the Renin-Angiotensin-Aldosterone System .Department of Cardiology, Harper University Hospital, Detroit, MI.

Reif, MC (09-20-2007. ) The Renin-Angiotensin-Aldosterone System: Why Do We Have It and Do We Still Want It? .The Christ Hospital, Cincinnati, OH.

Reif, MC (10-04-2007. ) Common Challenges Related to Nephrology .Atlanta, GA.

Reif, MC (10-11-2007. ) Insider's Guide to Dyslipidemia: A Practical Guide to Global Risk Stratification and Lipid Management .Boston, MA. Conference. . Level:Prof. Org.

Reif, MC (12-12-2007. ) Update on Hypertension .Division of Nephrology, University of Kentucky, Lexington, KY.

Reif, MC (01-25-2008. ) Hypertension Update .Kettering Medical Center, Dayton, OH.

Reif, MC (04-24-2008. ) Revisiting the Role of Beta-Blockers in the Management of Hypertension - A Closer Look at Complicated Cases .Cleveland, OH. Conference. . Level:Prof. Org.

Reif, MC (09-12-2008. ) Hypertension Update .Dearborn County Hospital, Lawrenceburg, IN.

Reif, MC (11-09-2008. ) Atacand-ACC Advances in Heart Failure Treatment: Translating Evidence .New Orleans, LA. Professional Meeting. . Level:Prof. Org.

Reif, MC (12-04-2008. ) Hypertension Update .Wright Patterson Air Force Hospital, Dayton, OH.

Reif, MC (01-20-2009. ) Primary Hyperaldosteronism .Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati.

Reif, MC (03-06-2009. ) Update on Comprehensive Cardiovascular Risk Reduction: A Practical Guide to Managing Complex Patients in Primary Care .Indianapolis, IN. Professional Meeting. . Level:Prof. Org.

Reif, MC (03-25-2009. ) Hypertension for Neurologists .Division of Neurology, University of Cincinnati.

Reif, MC (05-29-2009. ) Lessons From Recent Trials in Hypertension and Stroke Prevention .Cincinnati, OH. Professional Meeting. . Level:Prof. Org.

Reif, MC (07-01-2009. ) Treatment of Hypertension: Why, When, and How .Department of Medicine, University of Cincinnati.

Reif, MC (03-20-2010. ) Update on the Management of Hypertension .College of Nursing, University of Cincinnati.

Reif, MC (07-07-2010. ) The Essence of Urine: The Urinary Concentrating and Diluting Mechanism .Department of Medicine, University of Cincinnati.

Reif, MC (10-15-2010. ) Update on the Management of Hypertension .Dearborn County Hospital, Lawrenceburg, IN.

Reif, MC (10-30-2010. ) Managing the Hypertensive Patient: Optimizing Therapy, Improving Outcomes and Meeting the Needs of Special Risk Populations .Baltimore, MD. Conference. . Level:Prof. Org.

Reif, MC (01-13-2011. ) Antihypertensive Therapy: Should We Measure Plasma Renin First? .The Christ Hospital, Cincinnati, OH.

Reif, MC (09-15-2011. ) Hyponatremia: Underrecognized or Overtreated? .St. Mary's Medical Center, Evansville, IN. Level:Regional

Honors and Awards

2010 Listed among Cincinnati's top doctors, Cincinnati Magazine

2009 Dean's Award for Excellence in Teaching Cincinnati College of Medicine

Keywords

renal, kidney, hypertension, salt metabolism, cardiovascular, hyperlipidemia, heart failure, nephrology

Contact Information

Academic - Medical Sciences Building
Room G263
CincinnatiĀ  Ohio, 45267
Phone: 513-558-5471
Fax: 513-558-4309
max.reif@uc.edu